Search PubMed⌕ Search

Biomedical subjects

G Cariti

Publications and source records attributed to G Cariti.

23 records · Page 2Linked to original sources
PubMed1985

Circulating acid-labile interferon in chronic versus acute, HBV-related liver disease. A marker of immune-mediated hepatocellular damage?

An acid-labile Interferon was detected in the circulation of 76.1% of patients with chronic active type B hepatitis, in 30% of patients with acute type B hepatitis, studied within 15 days from starting of symptoms, and in 25% of patients with acute type B hepatitis studied 4 to 6 weeks after the admission. Patients in the third group showing evidence of circulating Interferon had also a delayed recovery and tardive HBsAg clearance. Circulating immune complexes were detected in 85.7% of patients of the first group, in 63.3% of patients of the second group, and in 25% of patients of the third group. We suggest that an acid-labile circulating Interferon could be related to immune-mediated hepatocellular damage (evidenced by circulating immune complexes) in hepatitis B virus infection, gradually disappearing during recovery from acute hepatitis or persisting indefinitely in chronic active hepatitis.

Acute Disease↗
PubMedDate not supplied

[Histologic microbiopsy with 14 G needle in the diagnosis of breast lesions. Experience with 1000 cases].

PURPOSE: We report our experience with large core biopsy (LCB: 14-Gauge needles) of questionable or suspicious breast lesions detected at mammography and/or US. All biopsies were performed under instrumental guidance. We also report on technique, costs, time, advantages and disadvantages of the method and, finally, give precise indications on when and why large core biopsy is needed. MATERIAL AND METHODS: From january 1996 to may 2000 we performed 1000 microhistologic biopsies on breast lesions at the Unità Integrata di Senologia, Azienda Ospedaliera Careggi, Florence; 650 (65%) were non palpable lesions. Large core needles were used (14-Gauge caliber). In the majority of cases (70%) we used US guidance, in the others a stereotactic guidance was employed. RESULTS: Microhistologic biopsy allowed accurate characterization in most cases. Inadequate samples were obtained in 15 cases. The false negative rate was 6%. Surgery was needed to characterize the lesion unquestionably in 13 cases only. CONCLUSION: In agreement with literature reports, our results confirm large core biopsy as an adequate alternative to surgical biopsy and, to some extent, to FNAC, thanks to its moderate invasiveness, low costs, short execution time, little patient discomfort and high sensitivity (93.98%) and specificity (99.7%).

Biopsy, Needle↗
PubMedDate not supplied

Is a 3-month course of treatment with Peg-interferon effective in acute HCV hepatitis?

From February 2002, all the consecutive patients referring to the Department of Infectious Diseases, University of Turin, who were diagnosed as having acute HCV hepatitis were included in a prospective cohort study to evaluate if a 3-month course of Peg-Interferon alpha-2b (1.5 microg/kg once weekly) is effective to decrease the risk of progression to chronic disease. ALT and HCV-RNA measurements were scheduled at week 4 and 12 during treatment, and 24 weeks after the end of therapy. As of April 2003, ten patients were enrolled in the study. As to HCV genotype, seven patients had type 1 and 3 type non-1. At entry, median HCV-RNA level was 129500 (range: 3000-3100000 copies/mL) and six patients were symptomatic. Treatment was given within 20 days (range: 8-30) of the ALT peak. All patients completing 4 weeks (n = 9) and 12 weeks of treatment (n = 7) had undetectable HCV-RNA. Five patients who completed the 24-week follow-up after the end of treatment had a sustained viral response with ALT levels within normal range. Therapy was well tolerated in all patients. Even if our data are not definitive, our results show that once-weekly administration of Peg-interferon alfa-2b in patients with acute HCV infection may be an effective and convenient regimen.

Acute Disease↗